ARCHIVES

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

This article is from The Cancer Letter archive.

Vol. 25 No. 7 | July 26, 2002

Download PDF Visit The Full Archive

Related Articles

New Funding Mechanisms – Cooperative Agreement, Consortium Grant – Proposed For Clinical Groups

April 6, 1979

NCI Appropriations Still Hung Up

September 30, 1977

DCPC Advisors Commit $32 Mil. To Chemoprevention

June 7, 1991

National Breast Cancer Coalition Sets Goal To End Breast Cancer By Jan. 1, 2020

September 24, 2010

NIH Construction: Clinton, NIH Officials Dedicate Vaccine Research Center

June 11, 1999

Davis Denies “Cherry-Picking” Data To Support Her Claims.

August 1, 2008